AR, androgen receptor, 367

N. diseases: 854; N. variants: 163
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway? 28424556 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Thus, AR's function as a novel ETS-1 co-activator or potentially therapeutic target of HCC has been demonstrated. 29312607 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE The survival analysis showed that high AR mRNA is associated with poor survival of stomach adenocarcinoma and low-grade glioma, but better survival of adrenocortical carcinoma, kidney renal clear cell carcinoma, acute myeloid leukemia, liver hepatocellular carcinoma, ovarian serous cystadenocarcinoma, and skin cutaneous melanoma based on AR mRNA, protein or AR-score. 31759122 2020
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE An AR antagonist was able to block this process, suggesting that AR activation in AR-positive HCC may be therapeutically inhibited as a potential intervention strategy. 22819717 2012
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE In this report we describe an androgen receptor assay that utilizes the HepG2 human hepatoma cell line transiently transfected with the human androgen receptor and an androgen-responsive reporter. 9705896 1998
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 PosttranslationalModification disease BEFREE However, the regulatory effects of AR on epigenetic mediators in HCC remain ill-defined. 30150059 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 GeneticVariation disease BEFREE Polymorphisms at the androgen receptor-regulating genes and cytokine genes are possible host factors associated with HCC. 16673293 2006
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 GeneticVariation disease BEFREE Our study elucidates a novel mechanism underlying the higher risk of HCC in obese/NAFLD males, through specific DAGs enriched by hepatic lipogenesis to increase the transcriptional activity of hepatic AR, a confirmed risk factor for male HCC. 31455870 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 GeneticVariation disease BEFREE We investigated the association of a trinucleotide (CAG) repeat in the androgen receptor (AR) gene (located on the X chromosome) termed "AR-CAG repeats," levels of plasma testosterone, and the risk of HCC in Taiwanese men. 11121465 2000
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 GeneticVariation disease BEFREE In conclusion, the mis-sense somatic mutations of AR were rare in HCC but the TNR change was a more common one, which exclusively occurred in males. 17230529 2007
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE Finally, the STAT3-AR-CCRK-mTORC1 pathway components are concordantly over-expressed in human NASH-associated HCCs. 30523261 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Together, these preclinical findings suggest that hypoxia may increase the HCC CSC population via altering the AR/miR-520f-3p/SOX9 signaling, and targeting this newly identified signaling with the small molecule, miR-520f-3p, may help in the development of the novel therapy to better suppress the HCC progression. 30448543 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Here we sought to explore the roles and mechanisms of acetylcholine (Ach) and androgen receptor (AR) on regulating the fate determinations of HCC. 23620780 2013
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE In addition, TSPY1 and androgen receptor (AR) were co-expressed simultaneously in HCC cell lines as well as in HCC tissue. 24586606 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE Therefore, the evaluation of AR expression in HCC patients might be relevant for the planning of clinical studies on anti-androgen therapies, which might be useful only in the cases in which a high level of AR mRNA is detected, considering the high heterogeneity of AR mRNA levels which characterizes HCC samples. 12371139 2002
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Moreover, AR directly interacts in vivo with androgen-responsive elements in the regions of promoter and exon 2 of PEG10 gene in HCC cell lines. 17369855 2007
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 GeneticVariation disease BEFREE Plasma testosterone and estradiol levels and genetic polymorphisms in the hormone-related factors cytochrome P450c17 alpha (CYP17, A1 versus A2 alleles), steroid 5 alpha-reductase type II (SRD5A2, valine [V] versus leucine [L] alleles), and androgen receptor (AR, number of CAG repeats) were assayed among 119 case patients who were diagnosed with HCC during 12 years of follow-up and 238 control subjects.All statistical tests were two-sided. 11698569 2001
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 GeneticVariation disease BEFREE However, few studies have addressed the abnormalities of X chromosome in hepatocellular carcinoma (HCC) except sporadic reports on the deletion of band F1 in X chromosome, and the clonal analysis of methylation pattern of the X chromosome-linked human androgen receptor gene. 14969851 2004
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE None of the hepatoma cell lines studied, however, expressed detectable levels of androgen receptor messenger RNA except for the SK-HEP-1 hepatoma cell line. 1648543 1991
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE These results not only help to explain the AR roles in the gender disparity of HCC but also provide a potential new therapy to better suppress HCC via combining sorafenib with NK cell-related immunotherapy. 26939703 2016
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Hepatocellular carcinoma (HCC) is a predominantly male disease in which the androgen receptor (AR) serves an important pathogenic role in hepatocarcinogenesis. 28599448 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE These results demonstrate that targeting the AR, rather than the androgen, could be developed as a new therapy to battle HBV-induced HCC. 20484730 2010
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 GeneticVariation disease BEFREE The association between harboring 2 AR alleles containing longer CAG repeats and HCC was more striking among HBV carriers (age-adjusted OR for more than 22 repeats, 2.23; 95% CI, 1.14-4.34) and particularly prominent among HBV carriers under age 53 years (age-adjusted OR, 3.16; 95% CI, 1.13-8.82). 12085360 2002
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Combination of sorafenib with AR inhibitors might represent a potential treatment for patients with advanced HCC. 28475115 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE HBx-induced androgen receptor expression in HBV-associated hepatocarcinoma is independent of the methylation status of its promoter. 21117024 2011